A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2014
At a glance
- Drugs MK 0557 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Merck & Co
- 04 Nov 2008 Trial end date changed from Nov 2008 to Oct 2008 as reported by Clinicaltrials.gov.
- 04 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2008 Planned end date changed from 1 Aug 2008 to 1 Nov 2008 as reported by ClinicalTrials.gov.